Copies of letters sent to healthcare professionals in May 2013, to inform of new safety information and advice
| Date sent | Medicine | Safety information |
|---|---|---|
|
13 May 2013 |
Restricted indications, new contraindications, and warnings relating to cardiovascular risks |
|
|
15 May 2013 |
Avastin (Bevacizumab) |
Cases of necrotising fasciitis, including fatal outcomes |
|
20 May 2013 |
Samsca (Tolvaptan) |
Risk of liver injury (seen at high dose in an unlicensed indication) |
